Skip to main content
SpringerLink
Log in

Stem Cell Sources for Allogeneic Transplantation

  • Chapter
Hematopoietic Stem Cell Transplantation

Part of the book series: Contemporary Hematology ((CH))

  • 1314 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schmitz N, Linch DC, Dreger P et al. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 1996;347:353–357.

    Article  PubMed  CAS  Google Scholar 

  2. Vose JM, Sharp G, Chan WC et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol. 2002;20:2344–2352.

    Article  PubMed  Google Scholar 

  3. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A. EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Transplant. 2006;37:1069–1085.

    Article  PubMed  CAS  Google Scholar 

  4. Abkowitz JL. Can human hematopoietic stem cells become skin, gut, or liver cells? N Engl J Med. 2002;346:770–772.

    Article  PubMed  Google Scholar 

  5. Bensinger WI, Price TH, Dale DC et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood. 1993;81:1883–1889.

    PubMed  CAS  Google Scholar 

  6. McCullough J, Clay M, Herr G, Smith J, Stroncek D. Effects of granulocyte-colony-stimulating factor on potential normal granulocyte donors. Transfusion. 1999;39:1136–1140.

    Article  PubMed  CAS  Google Scholar 

  7. Murata M, Harada M, Kato S et al. Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors. Bone Marrow Transplant. 1999;24:1065–1071.

    Article  PubMed  CAS  Google Scholar 

  8. Demirer T, Ayli M, Ozcan M et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol. 2002;116:468–474.

    Article  PubMed  CAS  Google Scholar 

  9. Gazitt Y. Comparison between granulocyte colony-stimulating factor and granulo-cyte-macrophage colony-stimulating factor in the mobilization of peripheral blood stem cells. Curr Opin Hematol. 2002;9:190–198.

    Article  PubMed  Google Scholar 

  10. Kröger N, Renges H, Sonnenberg S et al. Stem cell mobilization with 16 μg/kg vs 10 μg/kg of G-CSF for allogeneic transplantation in healthy donors. Bone Marrow Transplant. 2002;29:727–730.

    Article  PubMed  Google Scholar 

  11. Thomas J, Liu F, Link DC. Mechanisms of mobilization of hematopoietic progenitors with granulocyte colony-stimulating factor. Curr Opin Hematol. 2002;9:183–189.

    Article  PubMed  Google Scholar 

  12. Papayannopoulou T. Mechanisms of stem-/progenitor-cell mobilization: the anti-VLA-4 paradigm. Semin Hematol. 2000;37:11–18.

    Article  PubMed  CAS  Google Scholar 

  13. Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood. 2001;98:1289–1297.

    Article  PubMed  CAS  Google Scholar 

  14. Broxmeyer HE, Orschell CM, Clapp DW et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 2005;201:1307–1318.

    Article  PubMed  CAS  Google Scholar 

  15. Devine SM, Flomenberg N, Vesole DH et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-hodgkin's lymphoma. Journal of Clinical Oncology. 2004;22:1095–1102.

    Article  PubMed  CAS  Google Scholar 

  16. Devine SM, Vij R, Todt L et al. HLA-matched sibling donor stem cell mobilization can be safely and effectively reduced from a five day to a one day process by a direct antagonist of the CXCR4/SDF-1 interaction. Blood. 2006;108:20a.

    Google Scholar 

  17. Steidl U, Kronenwett R, Rohr UP et al. Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34(+) hematopoietic stem cells. Blood. 2002;99:2037–2044.

    Article  PubMed  CAS  Google Scholar 

  18. Gyger M, Stuart RK, Perreault C. Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor. Bone Marrow Transplant. 2000;26:1–16.

    Article  PubMed  CAS  Google Scholar 

  19. Singhal S, Powles R, Kulkarni S et al. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs. blood stem cell transplantation. Bone Marrow Transplant. 2000;25:501–505.

    Article  PubMed  CAS  Google Scholar 

  20. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol. 2000;18:1360–1377.

    PubMed  CAS  Google Scholar 

  21. Mavroudis D, Read E, Cottler-Fox M et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood. 1996;88:3223–3229.

    PubMed  CAS  Google Scholar 

  22. Ilhan O, Arslan Ö, Arat M et al. The impact of the CD34+ cell dose on engraft-ment in allogeneic peripheral blood stem cell transplantation. Transfusion Sci. 1999;20:69–71.

    Article  CAS  Google Scholar 

  23. Zaucha JM, Gooley T, Bensinger WI et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood. 2001;98:3221–3227.

    Article  PubMed  CAS  Google Scholar 

  24. Bittencourt H, Rocha V, Chevret S et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood. 2002;99:2726–2733.

    Article  PubMed  CAS  Google Scholar 

  25. Miflin G, Russell NH, Hutchinson RM et al. Allogeneic peripheral blood stem cell transplantation for haematological malignancies — an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant. 1997;19:9–13.

    Article  PubMed  CAS  Google Scholar 

  26. Shpall EJ, Champlin R, Glaspy JA. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant. 1998;4:84–92.

    Article  PubMed  CAS  Google Scholar 

  27. Blaise D, Kuentz M, Fortanier C et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Société Française de Greffe de Moelle. J Clin Oncol. 2000;18:537–546.

    PubMed  CAS  Google Scholar 

  28. Schmitz N, Beksac M, Hasenclever D et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood. 2002;100:761–767.

    Article  PubMed  CAS  Google Scholar 

  29. Powles R, Mehta J, Kulkarni S et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomized trial. Lancet. 2000;335:1231–1237.

    Article  Google Scholar 

  30. Champlin RE, Schmitz N, Horowitz MM et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood. 2000;95:3702–3709.

    PubMed  CAS  Google Scholar 

  31. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. Journal of Clinical Oncology. 2005;23:5074–5087.

    Article  Google Scholar 

  32. Couban S, Simpson DR, Barnett MJ et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood. 2002;100:1525–1531.

    Article  PubMed  CAS  Google Scholar 

  33. Anderlini P, Körbling M, Dale D et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood. 1997;90:903–908.

    PubMed  CAS  Google Scholar 

  34. Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344:175–181.

    Article  PubMed  CAS  Google Scholar 

  35. Heldal D, Tjonnfjord G, Brinch L et al. A randomized study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant. 2000;25:1129–1136.

    Article  PubMed  CAS  Google Scholar 

  36. Bennett CL, Waters TM, Stinson TJ et al. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;24:555–560.

    Article  PubMed  CAS  Google Scholar 

  37. Cutler C, Giri S, Jeyapalan S et al. Acute and chronic graft-versus-host disease after allogeneic peripheral- blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 2001;19:3685–3691.

    PubMed  CAS  Google Scholar 

  38. Horan JT, Liesveld JL, Fernandez ID et al. Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials. Bone Marrow Transplant. 2003;32:293–298.

    Article  PubMed  CAS  Google Scholar 

  39. Bacigalupo A, Zikos P, Van Lint M-T et al. Allogeneic bone marrow or peripheral blood cell transplants in adults with hematologic malignancies: a single-center experience. Exper Hematol. 1998;26:409–414.

    CAS  Google Scholar 

  40. Russell JA, Larratt L, Brown C et al. Allogeneic blood stem cells and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome. Bone Marrow Transplant. 1999;24:1177–1183.

    Article  PubMed  CAS  Google Scholar 

  41. Storek J, Gooley T, Siadak M et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood. 1997;90:4705–4709.

    PubMed  CAS  Google Scholar 

  42. Üstün C, Arslan Ö, Beksa÷ M et al. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse. Biol Blood Marrow Transplant. 1999;5:28–35.

    Article  PubMed  Google Scholar 

  43. Mahmoud H, Fahmy O, Kamel A et al. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 1999;24:355–358.

    Article  PubMed  CAS  Google Scholar 

  44. Vigorito AC, Azevedo WM, Marques JFC et al. A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant. 1998;22:1145–1151.

    Article  PubMed  CAS  Google Scholar 

  45. Vigorito AC, Marques Junior JF, Aranha FJ et al. A randomized, prospective c omparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of hematologic malignancies: an update. Haematologica. 2001;86:665–666.

    PubMed  CAS  Google Scholar 

  46. Kollman C, Howe CW, Anasetti C et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98:2043–2051.

    Article  PubMed  CAS  Google Scholar 

  47. Remberger M, Ringden O, Blau IW et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood. 2001;98:1739–1745.

    Article  PubMed  CAS  Google Scholar 

  48. Ringden O, Remberger M, Runde V et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood. 1999;94:455–464.

    PubMed  CAS  Google Scholar 

  49. Eapen M. Peripheral blood stem cells versus bone marrow for ablative transplantation. Biol Blood Marrow Transplant. 2007;13 Suppl 1:76–77.

    Article  Google Scholar 

  50. Anasetti C. A phase III randomized, multicenter trial comparing G-CSF mobilized peripheral blood stem cell with marrow transplantation from HLA compatible unrelated donors protocol document). Accessed at : http://bmtctn.def6.net/urd_pb_ vs_bm/. February, 2007.

    Google Scholar 

  51. Przepiorka D, Smith TL, Folloder J et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999;94:1465–1470.

    PubMed  CAS  Google Scholar 

  52. Przepiorka D, Anderlini P, Saliba R et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 2001;98:1695–1700.

    Article  PubMed  CAS  Google Scholar 

  53. Zeng D, Dejbakhash-Jones S, Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood. 1997;90:453–463.

    PubMed  CAS  Google Scholar 

  54. Pan L, Delmonte J Jr., Jalonen CK, Ferrara JLM. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood. 1995;86:4422–4429.

    PubMed  CAS  Google Scholar 

  55. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood. 2000;95:2484–2490.

    PubMed  CAS  Google Scholar 

  56. Reddy V, Hill GR, Pan L et al. G-CSF modulates cytokine profile of dendritic cells and decreases acute graft-versus-host disease through effects on the donor rather than the recipient. Transplant. 2000;69:691–693.

    Article  CAS  Google Scholar 

  57. Zeng D, Hoffmann P, Lan F et al. Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact on allogeneic bone marrow transplantation. Blood. 2002;99:1449–1457.

    Article  PubMed  CAS  Google Scholar 

  58. Schmitz N, Eapen M, Horowitz MM et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood. 2006;108:4288–4290.

    Article  PubMed  CAS  Google Scholar 

  59. Schmitz N, Beksac M, Bacigalupo A et al. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica. 2005;90:643–648.

    PubMed  CAS  Google Scholar 

  60. Urbano-Ispizua A, Carreras E, Marin P et al. Allogeneic transplantation of CD34(+) selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34(+) cells? Blood. 2001;98:2352–2357.

    Article  PubMed  CAS  Google Scholar 

  61. Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-host disease while preserving graft-versus- leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood. 2002;99:3083–3088.

    Article  PubMed  CAS  Google Scholar 

  62. Uckun FM, Roers BA, Waurzyniak B, Liu X-P, Cetkovic-Cvrlje M. Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model. Blood. 2002;99:4192–4199.

    Article  PubMed  CAS  Google Scholar 

  63. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 2001;97:2923–2931.

    Article  PubMed  CAS  Google Scholar 

  64. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562.

    PubMed  CAS  Google Scholar 

  65. Sullivan KM, Weiden PL, Storb R et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantationfrom HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73:1720–1728.

    PubMed  CAS  Google Scholar 

  66. Le Blanc R, Montminy-Metivier S, Belanger R et al. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant. 2001;28:841–848.

    Article  PubMed  Google Scholar 

  67. Brunet S, Urbano-Ispizua A, Ojeda E et al. Favorable effect of the combination of acute and chronic graft-versus- host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies. Br J Haematol. 2001;114:544–550.

    Article  PubMed  CAS  Google Scholar 

  68. Miklos DB, Kim HT, Miller KH et al. Antibody responses to H-Y minor histo-compatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005;105:2973–2978.

    Article  PubMed  CAS  Google Scholar 

  69. Körbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood. 1995;85:1659–1665.

    PubMed  Google Scholar 

  70. Elmaagacli A, Beelen DW, Opalka B, Seeber S, Schaefer UW. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood. 1999;94:384–389.

    PubMed  CAS  Google Scholar 

  71. Elmaagacli AH, Basoglu S, Peceny R et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood. 2002;99:1130–1135.

    PubMed  CAS  Google Scholar 

  72. Corradini P, Voena C, Tarella C et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol. 1999;17:208–215.

    PubMed  CAS  Google Scholar 

  73. Powles R, Mehta J, Treleaven J et al. Blood or BM for allogeneic transplantation from HLA-identical siblings? Extended follow-up of a randomized study confirms significantly higher relapse with BM. Blood. 2000;96:196a [Abstract].

    Google Scholar 

  74. Heldal D, Brinch L, Tjonnfjord G et al. Fewer relapses and increased chronic GVHD in patients transplanted with blood stem cells: a 5-year follow-up in a single center study. Bone Marrow Transplant. 2003;32:257–264.

    Article  PubMed  CAS  Google Scholar 

  75. Hochberg EP, Chillemi AC, Wu CJ et al. Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. Blood. 2001;98:1116–1121.

    Article  PubMed  CAS  Google Scholar 

  76. Wu CJ, Chillemi A, Alyea EP et al. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood. 2000;95:352–359.

    PubMed  CAS  Google Scholar 

  77. Fujimaki K, Maruta A, Yoshida M et al. Immune reconstitution assessed during five years after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001;27:1275–1281.

    Article  PubMed  CAS  Google Scholar 

  78. Shenoy S, Mohanakumar T, Todd G et al. Immune reconstitution following allogeneic peripheral blood stem cell transplants. Bone Marrow Transplant. 1999;23:335–346.

    Article  PubMed  CAS  Google Scholar 

  79. Maury S, Mary JY, Rabian C et al. Prolonged immune deficiency following alloge-neic stem cell transplantation: risk factors and complications in adult patients. Br J Haematol. 2001;115:630–641.

    Article  PubMed  CAS  Google Scholar 

  80. Storek J, Gooley T, Witherspoon RP, Sullivan KM, Storb R. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol. 1997;54:131–138.

    Article  PubMed  CAS  Google Scholar 

  81. Storek J, Espino G, Dawson MA et al. Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. Blood. 2000;96:3290–3293.

    PubMed  CAS  Google Scholar 

  82. Tayebi H, Tiberghien P, Ferrand C et al. Allogeneic peripheral blood stem cell transplantation results in less alteration of early T cell compartment homeostasis than bone marrow transplantation. Bone Marrow Transplant. 2001;27:167–175.

    Article  PubMed  CAS  Google Scholar 

  83. Schmitz N, Bacigalupo A, Hasenclever D et al. Allogeneic bone marrow transplantation vs. filgrastim-mobilized peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomized multicenter trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1998;21:995–1003.

    Article  PubMed  CAS  Google Scholar 

  84. Storek J, Dawson MA, Storer B et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood. 2001;97:3380–3389.

    Article  PubMed  CAS  Google Scholar 

  85. Storek J, Witherspoon RP, Maloney DG, Chauncey TR, Storb R. Improved recon-stitution of CD4 T cells and B cells but worsened reconstitution of serum IgG levels after allogeneic transplantation of blood stem cells instead of marrow. Blood. 1997;89:3891–3893.

    PubMed  CAS  Google Scholar 

  86. Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood. 1996;88:2775–2779.

    PubMed  CAS  Google Scholar 

  87. Trenschel R, Bernier M, Delforge A et al. Myeloid and lymphoid recovery following allogeneic bone marrow transplantation: a comparative study between related, unrelated bone marrow and allogeneic peripheral stem cell transplantation. Leuk Lymphoma. 1998;30:325–352.

    PubMed  CAS  Google Scholar 

  88. Abrahamsen IW, Somme S, Heldal D et al. Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host disease. Haematologica. 2005;90:86–93.

    PubMed  Google Scholar 

  89. Eapen M, Horowitz MM, Klein JP et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol. 2004;22:4872–4880.

    Article  PubMed  Google Scholar 

  90. Anderlini P, Rizzo JD, Nugent ML et al. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant. 2001;27:689–692.

    Article  PubMed  CAS  Google Scholar 

  91. Becker PS, Wagle M, Matous S et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant. 1997;3:45–49.

    PubMed  CAS  Google Scholar 

  92. de la Rubia J, Martinez C, Solano C et al. Administration of recombinant human granulocyte colony-stimulating factor to normal donors: results of the Spanish National Donor Registry. Bone Marrow Transplant. 1999;24:723–728.

    Article  Google Scholar 

  93. Cavallaro AM, Lilleby K, Majolino I et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant. 2000;25:85–89.

    Article  PubMed  CAS  Google Scholar 

  94. Rowley SD, Donaldson G, Lilleby K, Bensinger WI, Appelbaum FR. Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood. 2001;97:2541–2548.

    Article  PubMed  CAS  Google Scholar 

  95. Bredeson C, Leger C, Couban S et al. An evaluation of the donor experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allografting. Biol Blood Marrow Transplant. 2004;10:405–414.

    Article  PubMed  Google Scholar 

  96. Karlsson L, Quinlan D, Guo D et al. Mobilized blood cells vs bone marrow harvest: experience compared in 171 donors with particular reference to pain and fatigue. Bone Marrow Transplant. 2004;33:709–713.

    Article  PubMed  CAS  Google Scholar 

  97. Auquier P, Macquart-Moulin G, Moatti JP et al. Comparison of anxiety, pain and discomfort in two procedures of hematopoietic stem cell collection: leukacytapheresis and bone marrow harvest. Bone Marrow Transplant. 1995;16:541–547.

    PubMed  CAS  Google Scholar 

  98. Couban S, Messner HA, Andreou P et al. Bone marrow mobilized with granulocyte colony-stimulating factor in related allogeneic transplant recipients: a study of 29 patients. Biol Blood Marrow Transplant. 2000;6:422–427.

    Article  PubMed  CAS  Google Scholar 

  99. Jacobs P, Hailey D, Turner R, MacLean N. Allogeneic stem cell transplantation. An economic comparison of bone marrow, peripheral blood, and cord blood technologies. Int J Technol Assess Health Care. 2000;16:874–884.

    Article  PubMed  CAS  Google Scholar 

  100. Laughlin MJ, Eapen M, Rubinstein P et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265–2275.

    Article  PubMed  CAS  Google Scholar 

  101. Rocha V, Labopin M, Sanz G et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351:2276–2285.

    Article  PubMed  CAS  Google Scholar 

  102. Takahashi S, Ooi J, Tomonari A et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood. 2007;109:1322–1330.

    Article  PubMed  CAS  Google Scholar 

  103. Parody R, Martino R, Rovira M et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant. 2006;12:734–748.

    Article  PubMed  Google Scholar 

  104. Link H, Arseniev L, Bahre O et al. Combined transplantation of allogeneic bone marrow and CD34+ blood cells. Blood. 1995;86:2500–2508.

    PubMed  CAS  Google Scholar 

  105. Szer J, Curtis DJ, Bardy PG, Grigg AP. The addition of allogeneic peripheral blood-derived progenitor cells to bone marrow for transplantation: results of a randomized clinical trial. Aust N Z J Med. 1999;29:487–493.

    Article  PubMed  CAS  Google Scholar 

  106. Morton J, Hutchins C, Durrant S. Granulocyte-colony-stimulating factor G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood. 2001;98:3186–3191.

    Article  PubMed  CAS  Google Scholar 

  107. Ji SQ, Chen HR, Xun CQ et al. The effect of G-CSF-stimulated donor marrow on engraftment and incidence of graft-versus-host disease in allogeneic bone marrow transplantation. Clin Transplant. 2001;15:317–323.

    Article  PubMed  CAS  Google Scholar 

  108. Isola L, Scigliano E, Fruchtman S. Long-term follow-up after allogeneic granu-locyte colony-stimulating factor-primed bone marrow transplantation. Biol Blood Marrow Transplant. 2000;6:428–433.

    Article  PubMed  CAS  Google Scholar 

  109. Serody JS, Sparks SD, Lin Y et al. Comparison of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells and G-CSF-stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation. Biol Blood Marrow Transplant. 2000;6:434–440.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology Malignancies, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

    Corey Cutler

Authors
  1. Corey Cutler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, 44 Binney Street, DFCI D1B30, Boston, MA, 02115, USA

    Robert J. Soiffer MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Cutler, C. (2008). Stem Cell Sources for Allogeneic Transplantation. In: Soiffer, R.J. (eds) Hematopoietic Stem Cell Transplantation. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-438-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-438-4_12

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-05-3

  • Online ISBN: 978-1-59745-438-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation